FOXP3 and myeloid sarcoma: Theseagents can lessen some of the MS symptoms byinhibition of immune cell activation, decrease ofproinflammatory cytokines production, matrixmetalloproteinase activity reduction, induction ofanti-inflammatory cytokine secretion (64), andby increasing expression of Foxp3 in CD4+ andCD25+Treg cells (65).